Skip to main content
. 2022 Mar 14;14(6):1479. doi: 10.3390/cancers14061479

Figure 1.

Figure 1

Case study of a prostate cancer (PC) patient who was pretreated with a radical prostatectomy, seminal vesicle removal, and lymphadenectomy (pT3a, pN0 [0/14], cM0, G3) in October 2020 with an initial prostate-specific antigen (PSA) of 6.77 ng/mL. Postoperatively incomplete PSA drop to 0.08 ng/mL. In April 2021 (time of PSMA imaging), the PSA level rose again to 0.197 ng/mL. [18F]PSMA-1007 positron-emission tomography/computed tomography (PET/CT) shows a local recurrent PC-lesion near the base on the right in the former seminal vesicle with high prostate-specific membrane antigen (PSMA)-avidity (maximum standardized uptake value/SUVmax of 24.3 in the routine images and of 32.4 in the late-stage images) as a correlate of the biochemical recurrence (BCR). (The imaging and data were collected from a Practice of Radiology and Nuclear Medicine in Cologne/Germany, named “Praxis im KölnTriangle”).